General Information
Drug ID
DR00584
Drug Name
Amprenavir
Synonyms
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furyl ((alphaS)-alpha-((1R-1-hydroxy-2-(N(sup 1)-isobutylsulfanilamido)ethyl)phenethyl)carbamate; (3S)-tetrahydro-3-furyl N-[(1S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxy-propyl]carbamate; (3S-(3R*(1R*,2S*)))-(3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate; 4-Amino-N-((2 syn,3S)-2-hydroxy-4-phenyl-3-((S)-tetrahydrofuran-3-yloxycarbonylamino)-butyl)-N-isobutyl-benzenesulfonamide; AMV; Agenerase; Agenerase (TM); Agenerase (TN); Amprenavir (JAN/USAN/INN); Amprenavir [USAN]; Amprenavir[usan]; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester; Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Galanthus nivalis agglutinin (GNA); Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, (3S)-tetrahydro-3-furanyl ester & Hippeastrum hybrid agglutinin(HHA); DRG-0258; GNA & Amprenavir; HHA & Amprenavir; KVX-478; Prozei; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; VX 478; VX-478; VX478; Vertex; Vertex VX478; [(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate; {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD11: 1C62.Z] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
3D MOL 2D MOL
Formula
C25H35N3O6S
Canonical SMILES
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
InChI
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1
InChIKey
YMARZQAQMVYCKC-OEMFJLHTSA-N
CAS Number
CAS 161814-49-9
Pharmaceutical Properties Molecular Weight 505.6 Topological Polar Surface Area 140
Heavy Atom Count 35 Rotatable Bond Count 12
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 8
XLogP
2.9
PubChem CID
65016
PubChem SID
10286 , 103179760 , 104178998 , 104253275 , 104332645 , 104829267 , 11528777 , 117549941 , 118048728 , 12014852 , 125267472 , 125310993 , 127310203 , 127310204 , 127310205 , 14835820 , 14884574 , 26697364 , 29215412 , 3727052 , 3727059 , 43121862 , 46392146 , 46393211 , 46507537 , 53790789 , 57315242 , 601727 , 628182 , 71821412 , 74965413 , 7847958 , 7885327 , 7978703 , 8030478 , 8189448 , 822019 , 85177028 , 85177034 , 85177055 , 92309266 , 93166556 , 97857368 , 99239834 , 99239838 , 99239842 , 99239846 , 99239847 , 99239854 , 99239856
ChEBI ID
ChEBI:40050
TTD Drug ID
D0A0OO
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Fosamprenavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.